Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Influenza: early-phase trial registry
27 of 157 indexed Influenza trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #70 of 28,707 conditions by registered trial count.
157 US clinical trials · 27 currently recruiting · #70 of 28,707 conditions by registered trial count
Influenza: 157 US clinical trials tracked, 27 recruiting.
Influenza is the subject of 157 registered US clinical trials on ClinicalTrials.gov, 27 of them currently open to new participants. 42 are in Phase 3-4 (later-stage) and 73 in Phase 1-2 (earlier-stage). The most active sponsor is National Institute of Allergy and Infectious Diseases (NIAID), running 36 of these trials.
Enrollment posture brief
Registry condition influenza
OPEN 27 | RECR 17% | LATE 42 | EARLY 73 | RANK #70 | SPON 36
Volume-matched condition peers
Nearest open-share peer: Arthritis, Rheumatoid (17% recruiting · 29 trials)
Influenza lists 27 open slots (17% of 157 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Influenza on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Influenza is recruiting below its size-band peers.
27 of 157 indexed trials (17.2%) are open to enrollment, against a 37.1% average across 139 conditions with 100+ trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Influenza research.
National Institute of Allergy and Infectious Diseases (NIAID) accounts for 36 of 157 trials (22.9%). 62 distinct sponsors appear on at least one study for this condition label.
-
Typical Influenza enrolment sits around 219 participants.
Median target enrolment is 219 among the 157 trials that report a genuine target (sentinel values excluded). 55 of those (35%) plan for fewer than 100 participants.
-
Influenza research is mostly interventional.
134 interventional and 23 observational studies make up this index (85.4% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
157 total, page 3 of 4
2010-2011 Trivalent Influenza Vaccine (TIV) in Pregnant Women
National Institute of Allergy and Infectious Diseases (NIAID)
NCT01173211
A Phase 2 Influenza A Challenge Study Following Oral Administration of an H1N1 HA Ad-Vector Seasonal Flu Vaccine
Vaxart
NCT02918006
Study to Assess the Safety, Pharmacokinetics, and Efficacy of Baloxavir Marboxil in Healthy Pediatric Participants With Influenza-Like Symptoms
Hoffmann-La Roche
NCT03629184
Immunogenicity and Safety of FluBlok Trivalent Recombinant Hemagglutinin Influenza Vaccine in Healthy Pediatrics
Protein Sciences Corporation
NCT00336453
A Study Evaluating the Safety and Tolerability of a Seasonal Influenza Vaccine Containing LIQ001
Liquidia Technologies
NCT01224262
Safety and Immunogenicity of Quadrivalent Recombinant Influenza Vaccine Formulations Containing Different H3 Hemagglutinin Antigens in Healthy Adult Subjects 18 to 30 Years of Age
Sanofi Pasteur, a Sanofi Company
NCT04144179
Proteomic Profiling for Influenza
National Institute of Allergy and Infectious Diseases (NIAID)
NCT00133588
Study of an Investigational Monoclonal Antibody, VIS410, in Subjects With Uncomplicated Influenza A
Visterra
NCT02989194
Influenza Vaccination in the Emergency Department
University of Arizona
NCT00822627
Safety, PK and Effectiveness of IV Peramivir Versus Oseltamivir in Pediatric Subjects With Uncomplicated Influenza
BioCryst Pharmaceuticals
NCT02369159
Seasonal Influenza DNA Vaccine Prime With Trivalent Inactivated Vaccine (TIV) Boost Compared to TIV Alone
National Institute of Allergy and Infectious Diseases (NIAID)
NCT01498718
Safety, Reactogenicity, and Immunogenicity of Inactivated Influenza A/H7/N7 Vaccine in Healthy Adults
National Institute of Allergy and Infectious Diseases (NIAID)
NCT00546585
Influenza Vaccine in Lung Transplant Patients - Antibody
University of Wisconsin, Madison
NCT04533139
A Study to Evaluate the Safety and Immune Responses to Fluzone® Vaccination
Sanofi Pasteur, a Sanofi Company
NCT00743275
Immunologic Response to Inactivated Vaccine for Novel H1N1 Virus
University of Rochester
NCT01023711
Influenza Vaccine in Pregnant Women
National Institute of Allergy and Infectious Diseases (NIAID)
NCT00905125
Safety and Dose Study of Peramivir for Influenza Treatment
National Institute of Allergy and Infectious Diseases (NIAID)
NCT00297050
Inactivated Influenza A/H9N2 Vaccine With and Without MF59 Adjuvant in Ambulatory Adults
National Institute of Allergy and Infectious Diseases (NIAID)
NCT00133471
Collection of Serum Samples From Children and Older Adults Receiving the 2019-2020 Formulations of Fluzone® Quadrivalent and Fluzone® High-Dose Influenza Vaccines, Respectively
Sanofi Pasteur, a Sanofi Company
NCT04109222
Sanofi Pasteur Quadrivalent Intradermal Influenza Vaccine Pregnancy Registry
Sanofi Pasteur, a Sanofi Company
NCT02554409
Oseltamivir Treatment for Children Less Than 24 Months of Age With Influenza
National Institute of Allergy and Infectious Diseases (NIAID)
NCT00391768
Plasmablast Trafficking and Antibody Response in Influenza Vaccination (SLVP021 2011-2014)
Stanford University
NCT02141581
Mucosal and Systemic Immunity After Viral Challenge of Healthy Volunteers Vaccinated With Inactivated Influenza Vaccine Via the Intranasal Versus Intramuscular Route
National Institute of Allergy and Infectious Diseases (NIAID)
NCT03845231
The Role of CD4+ Memory Phenotype, Memory, and Effector T Cells in Vaccination and Infection
Stanford University
NCT03453801
T-cell And General Immune Response to Seasonal Influenza Vaccine (SLVP018) - Year 1, 2009
Stanford University
NCT01987349
Safety, Tolerability, and PK of Escalating Doses of Flufirvitide-3 Dry Powder for Inhalation in Healthy Subjects
Autoimmune Technologies
NCT01990846
Safety and Immunogenicity Among Healthy Children Receiving Fluzone® Quadrivalent Influenza Virus Vaccine
Sanofi Pasteur, a Sanofi Company
NCT01946425
Safety and Immunogenicity Among Healthy Children Receiving Fluzone® Quadrivalent, Influenza Vaccine
Sanofi Pasteur, a Sanofi Company
NCT02222870
Single-ascending-dose Study of the Safety and Immunogenicity of NasoVAX
Altimmune
NCT03232567
Elderly Influenza Vaccine Immunogenicity Substudy
National Institute of Allergy and Infectious Diseases (NIAID)
NCT00170482
Evaluation of Free Air Portable Air Powered Respirator
Wake Forest University Health Sciences
NCT02487147
Phase 1 Safety and Immunogenicity Study in Healthy Adults of VAX125, a Recombinant HA-flagellin Influenza Vaccine
VaxInnate Corporation
NCT00730457
Study to Evaluate the Immune Responses of Trivalent Cold-Adapted Influenza Vaccine (CAIV-T) Compared With (TIV)
MedImmune
NCT00111579
Study of High-dose Influenza Vaccine Efficacy by Repeated Dosing In Gammopathy Patients
Yale University
NCT02267733
B-cell Immunity to Influenza (SLVP017)- Year 1, 2009
Stanford University
NCT02133781
Safety and Tolerability Study of GlaxoSmithKline (GSK)1557484A Vaccine in Adults at Occupational Risk for Influenza A (H5N1) Exposure
GlaxoSmithKline
NCT01788228
Influenza A 2009 H1N1 Challenge Study in Healthy Adults
National Institute of Allergy and Infectious Diseases (NIAID)
NCT01646138
Immune Responses to H5N1 Vaccine With and Without AS03 Adjuvant
National Institute of Allergy and Infectious Diseases (NIAID)
NCT01578317
A Study of VIS410 to Assess Safety and Pharmacokinetics
Visterra
NCT02045472
Effect of Age and Prior Immunity to Response to Seasonal Influenza Vaccines in Children
University of Rochester
NCT01246999
Phase IV Trial to Collect Safety Data and Sera for Immunogenicity Testing in Healthy Children Given Fluzone® Vaccine
Sanofi Pasteur, a Sanofi Company
NCT00561002
Phase II Study to Investigate the Kinetics of the Immune Response Generated by Influenza Virus Vaccine.
MedImmune
NCT00192309
Anti-Influenza Hyperimmune Intravenous Immunoglobulin Pilot Study (INSIGHT 005: Flu-IVIG Pilot)
National Institute of Allergy and Infectious Diseases (NIAID)
NCT02008578
Safety of and Immune Response to a Bird Flu Virus Vaccine (H9N2) in Healthy Adults (Study A)
National Institute of Allergy and Infectious Diseases (NIAID)
NCT00110279
Safety of Lactobacillus Rhamnosus GG Versus Placebo in Elderly Subjects Receiving Live Attenuated Influenza Vaccine
Patricia L. Hibberd
NCT01545349
H7N9 Boost in Healthy Adults
National Institute of Allergy and Infectious Diseases (NIAID)
NCT02586792
Safety, Tolerability, and Pharmacokinetics of SAB-176 in Healthy Participants
SAb Biotherapeutics
NCT04471038
Safety and Immune Response to Recombinant Live-Attenuated Influenza H2N2 Virus Vaccine
National Institute of Allergy and Infectious Diseases (NIAID)
NCT00722774
Safety of Synbiotics as Adjuvant to Influenza Vaccine in Elderly
Mayo Clinic
NCT01304771
Safety of and Immune Response to Recombinant Live-Attenuated Influenza H6N1 Virus Vaccine Vaccine
National Institute of Allergy and Infectious Diseases (NIAID)
NCT00734175
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 42 |
| Phase 2 | 31 |
| Phase 3 | 17 |
| Phase 4 | 25 |
Top Sponsors
Named interventions
Most-linked intervention names on Influenza records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Influenza trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Influenza page
157 registered trials, 27 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 27 Influenza trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- National Institute of Allergy and Infectious Diseases (NIAID) sponsors the most Influenza trials on record, review their full trial history before evaluating a specific study. See National Institute of Allergy and Infectious Diseases (NIAID)'s trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Influenza condition card totals 157 registered trials; most-linked intervention Placebo; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.